Zydus Cadila gets USFDA nod for DMARD drug
Zydus Cadila gets USFDA nod for DMARD drug Cadila Healthcare received US FDA nod for hydroxychloroquine sulfate tablets in the strength of 200 mg. The drug falls in the DMARD (disease modifying anti-rheumatic drug) segment and is used in the management of rheumatoid arthritis. > The sales of hydroxychloroquine sulfate tablets in the US market in 2006 as per NDC Health was estimated at USD 30 million.
The company will market the drug through its US subsidiary Zydus Pharmaceuticals (USA). The group received 27 approvals since the commencement of filing process in FY 2003-04. So far, the group has filed 65 ANDAs and 55 DMFs.
Shares of the company declined Rs 4.25, or 1.40%, to trade at Rs 299.05. The total volume of shares traded was 23,589 at the BSE.(Tuesday)
